Sutro Biopharma News

Sutro Biopharma Analyst Ratings

Benzinga06:15 ET

B of A Securities Initiates Coverage On Sutro Biopharma With Buy Rating, Announces Price Target of $12

Benzinga06:16 ET

Sutro Biopharma Analyst Ratings

BenzingaApr 3 08:21 ET

Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)

TipRanksApr 3 07:06 ET

Sutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising Pipeline

TipRanksApr 3 00:35 ET

Sutro Biopharma Analyst Ratings

BenzingaMar 28 07:42 ET

Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)

TipRanksMar 27 07:50 ET

Sutro Biopharma Analyst Ratings

BenzingaMar 27 07:40 ET

Sutro Biopharma's New Forum Selection Clause: Protecting Interests or Alienating Shareholders?

TipRanksMar 27 02:00 ET

Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating

MT NewswiresMar 26 07:13 ET

Sutro Biopharma Analyst Ratings

BenzingaMar 26 06:09 ET

Sutro Biopharma: A Stable Hold Amid Pipeline Execution and Short-Term Uncertainties

TipRanksMar 26 04:47 ET

Sutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical Pipeline

TipRanksMar 26 00:25 ET

TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)

TipRanksMar 25 22:15 ET

Sutro Biopharma: A Balanced Hold Rating Amid Pipeline Execution and Upcoming Data Catalysts

TipRanksFeb 29 06:29 ET

Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO)

TipRanksJan 22 15:50 ET

Sutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential Ambiguities

TipRanksJan 8 05:06 ET

Buy Rating Justified: Sutro Biopharma's Luvelta Shows Promise in PROC Treatment and Beyond

TipRanksJan 5 06:27 ET

Buy Rating for Sutro Biopharma: Promising Clinical Developments and Strategic Financial Strength

TipRanksDec 12, 2023 00:25 ET

Piper Sandler Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TipRanksNov 29, 2023 06:37 ET